Investigating the effect of intrauterine injection of platelets concentrated from plasma on the pregnancy rate of patients with a history of implantation failure in the in vitro fertilization cycle.

Determining the outcomes of sub-endometrial hysteroscopic injection of platelet-rich plasma in patients with repeated IVF cycle failures and a history of implantation issues

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130115012146N11

Enrollment

Registered

2025-02-03

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: Control group: In both the control and intervention groups, the following actions will take place: Ovarian stimulation and egg retrieval: All patients will undergo ovarian stimulation

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with a history of recurrent implantation failure Consent to participate in the study Ages between 20 to 40 years old Body mass index less than 30 kilograms per square meter, Normal Hysterosalpingography

Exclusion criteria

Exclusion criteria: Obesity (BMI over 35 kg/m2) Congenital anomalies of the untreated uterus Untreated hydrosalpinx Women with poor ovarian response based on the Bologna criteria. Thrombophilia Unmanaged endocrine and hematological disorders Thickness of the under meter is less than 8 millimeters. Women with blood disorders (leukemia, thrombocytopenia) Women with immunological disorders (antiphospholipid syndrome, thrombophilia) Women with hormonal disorders (diabetes, thyroid, hyperprolactinemia) Women with chromosomal and genetic abnormalities (hereditary or congenital defects) Women with kidney problems

Design outcomes

Primary

Measure	Time frame
Endometrial thickness. Timepoint: The eighth or ninth day of the cycle after entering the study. Method of measurement: Transvaginal ultrasound.;Ectopic pregnancy. Timepoint: 7 weeks after embryo transfer. Method of measurement: Transvaginal ultrasound.;Abortion. Timepoint: Seven weeks after embryo transfer. Method of measurement: Transvaginal ultrasound.;???Fetal anomaly. Timepoint: Until the 20th week of pregnancy. Method of measurement: Ultrasound.	—

Measure

Time frame

Endometrial thickness. Timepoint: The eighth or ninth day of the cycle after entering the study. Method of measurement: Transvaginal ultrasound.;Ectopic pregnancy. Timepoint: 7 weeks after embryo transfer. Method of measurement: Transvaginal ultrasound.;Abortion. Timepoint: Seven weeks after embryo transfer. Method of measurement: Transvaginal ultrasound.;???Fetal anomaly. Timepoint: Until the 20th week of pregnancy. Method of measurement: Ultrasound.

—

Secondary

Measure	Time frame
Chemical pregnancy rate. Timepoint: 2 weeks after embryo transfer. Method of measurement: HCG blood test.;Clinical pregnancy. Timepoint: Fetal heart activity monitoring in weeks 6 to 7 of pregnancy. Method of measurement: Transvaginal ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Laya Farzadi

Tabriz University of Medical Sciences

lahroudin@gmail.com+98 41 3553 9160

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026